Verbatim response from ChatGPT
Short answer: Mostly no — be very skeptical of compounded “GLP‑1 drops” or unapproved oral tablets. FDA‑approved oral semaglutide (Rybelsus) works because it uses a proprietary absorption technology; most compounded forms do not, so they are unlikely to reliably deliver an effective dose and carry safety/quality risks.
Why compounded oral GLP‑1s are a problem
- Peptides (GLP‑1 agonists) are normally destroyed in the stomach/intestines and have poor absorption. Rybelsus (oral semaglutide) succeeds because it contains an absorption enhancer (SNAC) and was tested in clinical trials. Most compounded products do not include or validate that technology.
- Compounded drops/tablets are not FDA‑approved; they lack the rigorous testing for potency, stability, purity and bioavailability. That means unpredictable dosing and efficacy.
- Compounded products can be contaminated or mislabeled. They are not subject to the same manufacturing oversight as brand medications.
- There are no large clinical trials proving that homemade/compounded oral GLP‑1 formulations are as safe or effective as approved products.
What does work (approved options)
- Rybelsus (semaglutide tablets) — the only FDA‑approved oral GLP‑1. Works for type 2 diabetes when taken exactly as directed (fasted, small sip of water, wait ~30 minutes before eating/other meds). Its glucose and weight effects are generally smaller than weekly injectable semaglutide at equivalent systemic exposure.
- Injectable GLP‑1 agonists — examples: Ozempic and Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly). Injectables (weekly) generally produce larger weight loss and stronger glucose lowering than oral semaglutide formulations.
- There is currently no FDA‑approved oral tirzepatide or other oral GLP‑1s besides Rybelsus.
Safety and monitoring
- GLP‑1 drugs have known side effects (nausea, vomiting, diarrhea, possible gallbladder issues, rare pancreatitis) and contraindications (personal/family history of medullary thyroid carcinoma or MEN2). Use should be supervised by a clinician.
- Using an unregulated compounded product increases the risk of side effects and makes monitoring difficult because you don’t know the true dose.
If cost/needle phobia is the issue
- Talk with your clinician: Rybelsus is an option if you want oral therapy and is proven. If you want more potent weight loss or better glycemic control, injectable options may be better.
- Manufacturers often have coupons or patient assistance programs (Novo Nordisk programs for Rybelsus/Ozempic/Wegovy; Lilly for Mounjaro). Some pharmacies offer injection training to reduce needle anxiety.
My recommendation
- Avoid compounded GLP‑1 drops/tablets from compounding pharmacies or online sellers. Use FDA‑approved options (Rybelsus for an oral GLP‑1; Ozempic/Wegovy/Mounjaro for injectables) under the care of your provider. If you’re thinking about a specific compounded product, tell your clinician and don’t start it without medical supervision.
If you want, tell me:
- Are you considering a specific product or have a prescription?
- Is your goal diabetes control or weight loss?
I can summarize the clinically approved choices and practical next steps (cost help, administration tips, what to discuss with your doctor).